International Biotechnology Trust (IBT:LN) offers investors access to the fast growing biotechnology sector through an actively managed, diversified fund. Its award winning fund managers are biotechnology specialists with over 50 years of experience in this specialist sector between them. As well as investing in a wide ranging portfolio of global quoted biotechnology stocks, IBT includes a small proportion of otherwise inaccessible carefully selected unquoted investments which have the potential to deliver additional returns over the long term. Excellent management teams, unique innovative products and strong potential for outperformance are the key criteria for inclusion in IBT’s diversified portfolio of assets.
External link for International Biotechnology Trust Plc
1 London Wall Place
London, England EC2Y 5AU, GB
International Biotechnology Trust Plc reposted this
Our most recent episode of Trust Issues features a discussion with International Biotechnology Trust Plc managers Ailsa Craig and Marek Poszepczynski on the opportunities for investors in the biotech sector. Listen here: https://lnkd.in/dSQPds2B Capital at risk.
International Biotechnology Trust Plc reposted this
Did you know the recent downturn in biotech shares has collectively been their worst run in history? I know. I. Am. Shocked! Which is why i sat down with my brilliant colleagues Ailsa Craig and Marek Poszepczynski who know everything there is to know about the biotech sector and more. So, if you want to find out what's been going on and why, and whether the slump can be arrested, listen the latest episode of the Investor Download. It's available wherever you get your podcasts. And don't forget to subscribe, rate and review us. New shows drop every other Thursday at 5pm GMT. You can listen to an extract of pod by playing the video below. Enjoy!
With the US election outcome looming, read our latest blog on its impact on the biotech sector. Healthcare has been a huge subject of debate in previous US elections, contributing to significant market volatility, but the topic is more muted this time. Clearly, it’s important to understand how different outcomes may impact the biotech sector. Here we take a look at what to expect, with help from the history books… Read more: https://lnkd.in/eANBiP7g #biotechnology #investmenttrusts #uselection Marketing material. For UK audiences only. Your capital is at risk with investing.
Make sure to register for tomorrow’s Asset TV UK Future Trends in Investment Trusts live event where IBT’s Managers Ailsa Craig and Marek Poszepczynski will be interviewed by Winterflood Securities' Emma Bird, CFA. Register here: https://lnkd.in/eKUQxj9k #biotech #investmenttrusts #futuretrends For UK investors only. Capital at risk.
In IBT’s recent blog we examine the health of the biotech sector. With signs of life in the funding environment and the quality of the listed biotech companies gradually improving, we take a broad look on the sector and how it is influencing the outlook for investors… Read more: https://okt.to/noDC5E #biotechnology #investmenttrusts Marketing material. For UK audiences only. Past performance is not a guide to future performance and may not be repeated. Please note forecasts are not a reliable indicator of future results and your capital is at risk with investing.
International Biotechnology Trust Plc reposted this
Ailsa Craig & Marek Poszepczynski, portfolio managers, International Biotechnology Trust Plc, assess the investment potential in breakthrough cancer treatments. https://lnkd.in/eJm-HigH
In our latest monthly blog, we take a look at the many reasons to be positive about the outlook for biotech investors in the years ahead... Following a challenging three years, the biotechnology sector has put in a much more encouraging performance in recent months. Valuations are still attractive, balance sheets look strong and there is an improved funding environment. Read our article to find out more - https://okt.to/oEu49s #biotechnology #investmenttrusts Marketing material. For UK audiences only. Past performance is not a guide to future performance and may not be repeated. Please note forecasts are not a reliable indicator of future results and your capital is at risk with investing.
In our latest monthly blog post, we mark IBT’s 30 year anniversary with a look at the transformation of cancer therapy. As IBT reaches this milestone, the speed of progress in cancer therapy shows no sign of slowing down. Indeed, as we regularly report, the pace of innovation in biotechnology more broadly continues to accelerate. Read article - https://okt.to/SXJ1zr #biotechnology #investmenttrusts Marketing material. For UK audiences only. Past performance is not a guide to future performance and may not be repeated. Please note forecasts are not a reliable indicator of future results and your capital is at risk with investing.
IBT portfolio manager Ailsa Craig joins interactive investor’s latest ‘On the Money’ podcast where she discusses weight-loss drugs, themes she’s favouring in biotech, and why she’s optimistic the sector will bounce back from its worst-ever bear market. Listen here: https://okt.to/3tsayn #biotechnology #podcast #markets Capital at risk. Past performance is not a guide to future performance and may not be repeated. Forecasts are not a reliable indicator for future results. For UK audiences only
In our latest monthly blog post, we explore the implications of global demographics on biotech. The increasingly complex demands of a global population that is growing older, richer and sicker, are driving rising demand for healthcare services in general and underpinning a particularly strong secular growth story in biotechnological innovation. Read more: https://okt.to/DW027i #biotechnology #investmenttrusts Marketing material. For UK audiences only. Past performance is not a guide to future performance and may not be repeated. Please note forecasts are not a reliable indicator of future results and your capital is at risk with investing.